...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >New Agents for the Management of Advanced HER2-Positive Breast Cancer
【24h】

New Agents for the Management of Advanced HER2-Positive Breast Cancer

机译：高级Her2阳性乳腺癌管理的新代理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent advances in the treatment of HER2-pos-itive metastatic breast cancer have dramatically improved outcomes. Clinicians need to understand how to position the most effective new regimens and manage their unique side effects, speakers said at JADPRO Live at APSHO. "The development of targeted biologies has been a major milestone in the treatment of HER2-positive metastatic breast cancer and has markedly improved survival," said Karen Herold, DNP, WHCNP-BC, FNP-BC, of Hoag Memorial Hospital Presbyterian, Newport Beach, California. Melanie Royce, MD, PhD, of the University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, updated listeners on the key clinical trials that led to the approval of pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1; Kadcyla), two monoclonal antibodies that recently joined lapatinib (Tykerb) and trastuzumab (Herceptin) in the HER2-positive treatment arena, while Dr. Herold discussed how to monitor for and manage side effects associated with these new agents.
机译：HER2阳性转移性乳腺癌治疗的最新进展显著改善了预后。在APSHO的JADPRO Live上，发言者说，临床医生需要了解如何定位最有效的新疗法，并管理其独特的副作用。加利福尼亚州新港海滩霍格长老会纪念医院的DNP、WHCNP-BC、FNP-BC、Karen Herold说：“靶向生物学的发展是治疗HER2阳性转移性乳腺癌的一个重要里程碑，并显著提高了生存率。”。Melanie Royce，MD，博士，新墨西哥大学综合癌症中心，阿尔伯克基，新墨西哥，更新了关键的临床试验，导致批准帕妥珠单抗（PERJETA）和ADO曲妥珠单抗EMTANSIN（T-Md1；KADLILCA），两个单克隆抗体，最近加入拉帕替尼（TykB）和曲妥珠单抗（赫赛汀）在HER2阳性治疗领域，Herold博士讨论了如何监测和管理与这些新药物相关的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号